Skip to content
PeptideFactSheets
FDA approved for specific usesStrong human evidence for approved uses

Plain-English fact sheet

Semaglutide

Also known as Ozempic, Wegovy, Rybelsus

Weight managementMetabolic healthHeart and kidney outcomes

Semaglutide is a GLP-1 receptor agonist with strong human evidence for specific FDA-approved uses, but each brand and formulation has its own label.

Quick answer

Semaglutide is the active ingredient in several FDA-approved prescription medicines. Approval is product- and use-specific; it does not make every semaglutide product or every claimed use approved.

By the PeptideFactSheets Editorial Team. Use the source links to verify status, evidence, risks, and unknowns; our editorial policyexplains the boundaries. Clinician review appears only when a named reviewer is shown.

What is Semaglutide?

Semaglutide is a manufactured peptide-like medicine that acts on the GLP-1 receptor, part of a signaling system involved in blood sugar, appetite, and digestion.

The active ingredient appears in different prescription products. Those products are not interchangeable in every context, and their FDA labels differ.

Why are people interested in it?

People commonly search for semaglutide because of its established roles in type 2 diabetes care and chronic weight management.

Researchers also study cardiovascular, kidney, liver, and other outcomes. A study result does not automatically create a new approved use.

Current regulatory status

FDA approved for specific uses

FDA-approved semaglutide products include products for type 2 diabetes and products for chronic weight management in eligible patients. Some labels include cardiovascular risk-reduction indications. Check the current label for the exact product and use.

What is it approved for?

  • Improving blood sugar control in specified people with type 2 diabetes
  • Chronic weight management in specified people with obesity or overweight
  • Reducing specified cardiovascular risks in certain labeled populations

FDA approval path

FDA approved

FDA approved for product-specific uses

FDA labels support specific semaglutide products for diabetes, chronic weight management, and selected cardiovascular risk-reduction uses. Other claimed uses still require their own evidence and review.

Step 7 of 7

  1. DiscoveryBasic research
  2. PreclinicalLab and animal work
  3. Phase 1Initial human testing
  4. Phase 2Condition-focused trials
  5. Phase 3Confirmatory trials
  6. FDA reviewApplication review
  7. ApprovedLabel-specific use

Timeline source basis

FDA prescribing information: WegovyFDA prescribing information: OzempicFDA: Wegovy cardiovascular risk-reduction approval

What is it being studied for?

Type 2 diabetes
Chronic weight management
Cardiovascular outcomes
Kidney outcomes
Metabolic liver disease

Investigational areas

  • Additional kidney, liver, cardiovascular, and neurobehavioral outcomes
  • Uses outside the population or indication of a particular FDA-approved label

Evidence snapshot

Strong human evidence for approved uses

Multiple large randomized trials support approved uses. Evidence for a specific goal must still be matched to the product, population, outcome, and current label.

Potential benefits being researched

  • Randomized trials show clinically meaningful benefits for the uses and populations described in approved labels.
  • Ongoing studies are asking whether benefits extend to additional conditions; those questions should remain separate from established indications.

Potential does not mean proven. Study design, population, endpoint, and regulatory review matter.

Known or possible risks

  • Common gastrointestinal effects can include nausea, vomiting, diarrhea, constipation, and abdominal discomfort.
  • Current labels contain important warnings and contraindications, including a boxed warning about thyroid C-cell tumors observed in rodents.
  • Other labeled concerns can include pancreatitis, gallbladder disease, kidney injury related to dehydration, and low blood sugar when combined with certain diabetes medicines.
  • Compounded products are not FDA-approved and do not undergo the same premarket review for safety, effectiveness, and quality.

What we still do not know

  • How every benefit-risk tradeoff changes across individual medical histories
  • Whether ongoing trials will support additional labeled indications
  • Very long-term outcomes for additional uses and broader populations
  • The safety, quality, and equivalence of unapproved products marketed as semaglutide

Related research updates

FDA approves tirzepatide for obstructive sleep apnea in adults with obesityRetatrutide Phase 3 program reports top-line results

Plain-English takeaway

Semaglutide has substantial human evidence and legitimate approved uses. The careful question is not simply whether semaglutide is approved, but which product, for whom, and for what exact use.

Research and reference links

Use these primary and reputable sources to verify status and read beyond this summary. Trial registries may list studies without proving a benefit.

  1. 1
    fdaFDA prescribing information: Wegovy

    Official semaglutide prescribing information for a chronic-weight-management product.

  2. 2
    fdaFDA prescribing information: Ozempic

    Official semaglutide prescribing information for a type 2 diabetes product.

  3. 3
    fdaFDA: Wegovy cardiovascular risk-reduction approval

    FDA announcement describing the approved indication and supporting evidence.

  4. 4
    clinical trialsClinicalTrials.gov: SELECT cardiovascular outcomes trial

    Registry record for the SELECT semaglutide cardiovascular outcomes trial.

  5. 5
    pubmedSELECT cardiovascular outcomes trial

    Peer-reviewed report of a large semaglutide cardiovascular outcomes trial.